Senate bill targets FDA citizen petition delays

What does this do?

This bill tightens rules around "citizen petitions," which let companies ask the FDA to take action and can be used to slow down approval of generic or biosimilar drugs. Anyone who wants to sue to block a generic drug approval must first file a citizen petition within 180 days of learning the relevant information, or a court must permanently dismiss their case. The FDA also gets a specific list of factors to help identify petitions filed mainly to delay a competitor rather than for genuine safety or scientific reasons.

Who does it affect?

Brand-name drug manufacturers who use citizen petitions as a competitive tool are most directly affected by the new limits. Generic and biosimilar drug makers, patients, and payers are also affected because the rules could change how quickly lower-cost drugs reach the market.

Why does it matter?

If the bill becomes law, courts would be required to throw out delay-related lawsuits that do not follow the new petition rules. The FDA would also have clearer authority to identify petitions filed as competitive tactics rather than for legitimate reasons.

Where does it stand?